Treatment with granulocyte colony-stimulating factor (G-CSF) plus erythropoietin may synergistically improve hemoglobin levels and reduce bone marrow apoptosis in patients with refractory anemia with ringed sideroblasts (RARS). Fasinduced caspase activity is increased in RARS bone marrow cells. We showed that G-CSF significantly reduced Fasmediated caspase-8 and caspase-3-like activity and the degree of nuclear apoptotic changes in bone marrow from nine RARS patients. A decrease in mitochondrial membrane potential and an increase in intracellular reactive oxygen species occurred in Fas-treated cells, but became significant only 24 h after changes in caspase activity and decrease in proliferation. G-CSF also reduced the magnitude of these late apoptotic changes. In CD34-selected normal cells, G-CSF induced myeloid colony growth, and an overall small decrease in the number of erythroid colonies. By contrast, G-CSF induced a 33-263% increase of erythroid colony formation in CD34
Introduction
The myelodysplastic syndromes (MDS) constitute a group of clonal stem cell disorders characterized by cytopenia, ineffective hematopoiesis and a risk of progression to acute myeloid leukemia (AML). Refractory anemia with ringed sideroblasts (RARS) represents a subtype of MDS, in which amorphous iron deposits accumulate in the mitochondria of the erythroid precursors. The mitochondria localize in a ring around the nucleus thus giving the erythroid progenitors the classical ringsideroblastic appearance. 1 Increased apoptosis of bone marrow progenitors is a hallmark of MDS, especially in subtypes with a low percentage of bone marrow blasts. [2] [3] [4] Treatment with granulocyte colony stimulating factor (G-CSF) in combination with erythropoietin (EPO) may synergistically improve hemoglobin levels and decrease the number of apoptotic bone marrow precursors, as shown in recent clinical studies. [5] [6] [7] [8] [9] Furthermore, G-CSF is used in the treatment of patients with congenital neutropenia, 10 and for stem cell mobilization. 11 However, the molecular mechanisms underlying these clinically beneficial effects are not fully understood. Various mechanisms for the increased spontaneous apoptosis in MDS have been proposed. Fas ligand (Fas-L)/Fas interaction has been shown to play a physiological role in the regulation of hematopoiesis 12, 13 and involvement of the Fas system was suggested as a reason for increased apoptosis in MDS. [14] [15] [16] [17] [18] For instance, changes in the microenvironment of the bone marrow coding for higher levels of tumor necrosis factor (TNF)-␣ and interferon (INF)-␥ may upregulate Fas on CD34
+ stem cells, which usually do not express this receptor 19, 20 and thereby enhance apoptosis. Increased levels of inflammatory cytokines, such as TNF-␣ and TGF-␤, has also been proposed to directly induce apoptosis in MDS. 21, 22 Finally, expression of apoptosis-related oncoproteins such as Bcl-2, Bcl-X L and c-Myc is altered in MDS. 23, 24 Caspases (cysteine proteases that cleave after aspartic acid) are a group of proteases that are expressed as inactive proenzymes in the cells and are activated by cleavage upon apoptosis induction. They can be divided into several groups based on their function in the cell. 25, 26 Initiator caspases, such as caspase-2, -8, -9 and -10 function upstream in the apoptotic pathway and activate other caspases. Effector caspases, including caspase-3, -6 and -7, operate downstream in the apoptotic pathway cleaving proteins in the cytoskeleton, cytoplasm and the nucleus. We and others have recently shown that caspase-3-like activity is increased in mononuclear bone marrow cells (MNC) isolated from MDS patients. [27] [28] [29] [30] [31] Mitochondria have been implicated as the central executioner and/or regulator of apoptosis. 32 In apoptotic cells a drop in the mitochondrial potential (⌬ m ) can be detected and the release of more than 10 different apoptogenic proteins, including cytochrome-c and apoptosis-inducing factor (AIF), from mitochondria into the cytosol has been described. Subsequent disruption of the electron transport chain leads to an increase of reactive oxygen species (ROS) inside the cell. 33 Discrepancies in the literature concerning the mechanism of enhanced cell death in MDS, as well as differences in the response rate to cytokine treatment among various clinical studies suggest that differences exist with regard to the various subtypes of MDS. In an attempt to resolve this issue, we recently performed an investigation of the apoptotic processes in a well-defined MDS subgroup (RARS). We found that erythroid apoptosis was initiated at the CD34 + stem cell level and that specific peptide-based caspase inhibitors reduced apoptosis and increased proliferation and erythroid colony growth in these patients. 27 On the other hand, we found no evidence that endogenous stimulation of the Fas receptor was responsible for the spontaneously reduced cell survival or erythroid maturation deficit in RARS.
G-CSF has a documented clinical effect in RARS, even though its mechanism is unclear. The aim of the present study was to investigate the in vitro effect of G-CSF on apoptotic processes and erythroid colony growth of bone marrow precursors isolated from patients with RARS. Since mitochondria 743 are morphologically abnormal in RARS, it was also interesting to study the time-relation between mitochondrial events and other apoptotic-related processes. Our data revealed that G-CSF inhibits Fas-triggered caspase activity, mitochondrial changes and apoptosis in these cells. Moreover, addition of G-CSF significantly increased erythroid colony growth from CD34 + cells.
Materials and methods

Patients and controls
Nine RARS patients with a mean age of 71 years were included in the study (Table 1) . Normal bone marrow samples were obtained from 15 individuals, healthy volunteers or hematologically healthy patients undergoing thorax surgery. Due to the limited yield of cells, not all experiments were performed on all samples. Informed consent was obtained from both patients and controls, and the study followed the guidelines of the local ethical committee of Karolinska Institutet.
Bone marrow samples and suspension cultures
Bone marrow needle aspirates (5-10 ml) were obtained from the posterior crista iliaca (RARS patients, healthy volunters) or sternum (thorax surgery patients). As described previously, 34 the aspirates were subjected to Lymphoprep (Nycomed, Oslo, Norway) density gradient centrifugation to isolate MNC. After washing, the cells were cultured in RPMI 1640 medium (GIBCO BRL, UK) supplemented with 10% fetal calf serum (GIBCO BRL). MNC were cultured untreated (control) or with addition of Fas-agonistic antibodies (clone CH-11, 1 g/ml, Medical Biological Laboratories, Japan) in presence or absence of G-CSF (Neupogen 100 ng/ml; Amgen, Stockholm, Sweden). Cell cultures were routinely checked for viability by trypan blue exclusion.
CD34 cell separation and colony assay
When MNC numbers were sufficiently high to allow a CD34 separation, the cells were separated based on CD34 positivity using the MiniMacs system (Miltenyi Biotec, Bergisch Gladbach, Germany), as previously described. 27 Aliquots of CD34 
+
Western blot
Cells were harvested at 4 and 24 h. Frozen cell samples were used for Western blot analysis. MNC (1 × 10 6 ) were washed in PBS and then resuspended in PBS containing broad-spectrum protease inhibitors (Complete Mini, Roche) before freezing to prevent artificial cleavage. 34 As described previously, 27 immunoblotting was performed using lysates of whole cells. The cells were thawed on ice, resuspended in lysis buffer and the lysates were disolved on 15% SDS polyacrylamide gels and transblotted to nitrocellulose membranes (Sartorius). After blocking and washing the membranes were stained with primary antibodies overnight at 4°C. The following day, after several washings before and after the incubation with secondary antibodies, the membranes were developed with an ECL kit (Amersham Pharmacia Biotech AB, Uppsala, Sweden), according to the manufacturer's instructions. Glyceraldehyde-3-phosphate dehydrogenase (G3PDH) was used as a marker for equal protein amount loaded on to the gel. G3PDH rabbit IgG (Trevigen, Gaithersburg, MD, USA) and pro-caspase-3 mouse IgG (gift from Dr DW Nicholson, Merck Frosst Center for Therapeutic Research, Quebec, Canada) were used as primary antibodies in 1:3000 and 1:5000 dilution, respectively. As secondary antibodies, peroxidase-conjugated goat anti-rabbit IgG and goat antimouse IgG from Pierce (Rockford, USA) were used at a concentration of 1:5000.
In vitro caspase enzyme assay
As described previously, 35 the measurement of DEVD-AMC and IETD-AMC (Peptide Institute, Osaka, Japan) cleavage was performed after 4 and 24 h in a fluorometric assay modified from Nicholson et al. 36 Briefly, 1 × 10 6 MNC were harvested, washed twice in PBS and frozen as a dry cell pellet at −80°C. For the assay, the cells were kept on ice and resuspended in 50 l PBS. The appropriate peptide substrate was combined in a standard reaction buffer containing 100 mM HEPES, 10% sucrose, 5 mM dithiothreitol (DTT), 10 −4 % octylphenoxy polyethoxy ethanol (NP-40) and 0.1% 3-[(3-cholamidopropyl) dimethylammonio]-1-propane sulfonate (CHAPS), (pH 7.25) and added to the cell lysates on a microtiter plate. Cleavage of the fluorogenic peptide substrate was monitored by AMC liberation in a Fluoroscan plate reader (Labsystems, Stockholm, Sweden) using 355 nm excitation and 460 nm emission wavelengths for a period of 30 min. Fluorescence units were converted to pmol of AMC using a standard curve generated with free AMC. Data from duplicate samples were then analyzed by linear regression.
TUNEL staining
After fixation in 4% neutral buffered formalin, cytospins were made with 100 000 cells per slide at day 4 (96 h incubation) and air-dried. For staining, the commercial In Situ Apoptosis Detection Kit (ApopTag; Oncor) was used. The cytospins were digested in equilibration buffer for 1 min at room temperature. Dioxigenin-dUTP was catalytically added to DNA by TdT enzyme (1 h at 37°C) and visualization of the reaction was done by incubation with antidioxigenin antibody conjugated to FITC (30 min at room temperature). Counterstaining was made with propidium iodide (0.6 g/ml DABCO antifade). The percentage of apoptotic cells (cells with FITC-positive nuclei were interpreted as apoptotic) was based on differential count of 200 nucleated cells.
Flow cytometry
GpA separation was performed using the MiniMacs system as described for CD34 + cells. After separation, the GpA negative cell fraction was a sufficiently homogenous cell population to be used for analysis of mitochondrial transmembrane potential (⌬ m ) and intracellular ROS concentration by FACS. The loss of ⌬ m was detected using the cationic fluorescent dye 3,3Јdihexyloxacarbocyanine iodide (DiOC 6 (3), 20 nM; Molecular Probes, Leiden, The Netherlands), which accumulates in mitochondria as a direct function of ⌬ m , ROS were visualized by the dye dihydroethidium (HE, 4 M, Molecular Probes), which is oxidized to the fluorescence-emitting substance ethidium in the presence of reactive oxygen species. Briefly, 5 × 10 5 cells were collected, spun down and resuspended in 500 l PBS containing the dyes. After 30 min incubation at 37°C in the dark, the cells were stored on ice and analyzed on a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA). Necrotic cells were excluded based on forward and side scatter criteria and data were calculated using the CellQuest software (Becton Dickinson).
Statistics
Results are given as mean values ± s.d. and also as median values + range. For comparison of related and unrelated samples, paired and unpaired t-test was used, respectively.
Results
G-CSF significantly reduces caspase-8 and caspase-3-like activity
Using the substrate IETD-AMC, caspase-8 activity was measured after 4 and 24 h of MNC incubation. At both time points the initiator caspase 8 activity increased after incubation with the Fas agonistic antibodies in patients and controls. The Fasinduced activity was significantly higher in the patients than in the controls (P = 0.03, all statistic data for the 4-h time points). G-CSF addition to the cultures reduced Fas-induced caspase-8 activity in the four patients tested (P = 0.11), while conclusions could not be drawn about the controls (Figure 1 ). In two patients and one control the activity after the combined addition of Fas antibody and G-CSF was lower than the activity in cultures incubated in medium alone.
DEVD-AMC was used to estimate the effector caspase-3-like activity after 4 and 24 h. After 4 h of Fas incubation, patient MNC showed a significantly higher increase in caspase-3-like activity than control MNC (P = 0.0007, Figure 2a) . Addition of G-CSF significantly reduced caspase-3-like activity in the RARS cultures (P = 0.02). Control samples were too few to analyze statistically, but a similar tendency was observed. In analogy with the 4 h data, an increase in caspase-3-like activity after Fas stimulation and a decrease after G-CSF addition could be seen after 24 h, although the increase after Fas stimulation was less pronounced (data not shown).
The caspase-3-like activity data could be confirmed by immunoblotting with an anti-caspase-3 antibody that detects the 32 kDa proform, as well as the 17 kDa subunit which corresponds to the active form of caspase-3 (Figure 2b ). Addition of Fas antibodies to the cultures resulted in an increase in the amount of the 17 kDa cleavage band. This increase was completely prevented by addition of G-CSF.
Only in one patient and one control did we obtain enough cells to also perform the caspase assay in separated CD34 After Fas ligation the loss of mitochondrial potential and increase of ROS in GpA-negative cells were late events in the apoptotic process compared to the early increase of caspase activity discussed above. After 15 h of incubation a minor decrease of the potential in the Fas-treated cultures could be detected (data not shown). Fas ligation for 40 h resulted in a drop in potential and an increase of ROS (Figure 3b) . Addition of G-CSF effectively prevented the changes caused by Fas receptor ligation.
Fas-induced nuclear DNA fragmentation is significantly enhanced in RARS and is reduced by G-CSF
Nuclear DNA fragmentation, as determined by mean TUNEL positivity, was higher in the patient samples than in the normal controls directly after cell separation (data not shown). TUNEL results at day 4 showed significantly more Fas-induced apoptosis in RARS than in normal MNC (P = 0.01, Figure 4) . Mean Fas-induced TUNEL positivity at this time point was 23.8 ± 7.1% for patients and 13.2 ± 5.6% for controls. G-CSF reduced Fas-induced apoptosis to the same extent in RARS and control samples, P = 0.02 for all samples, 0.09 and 0.08 for RARS, and control samples, respectively (Figure 4) . Hence, these TUNEL data confirmed other apoptotic parameters Leukemia (caspase activation and mitochondrial alterations) as described above.
G-CSF promotes proliferation of Fas-treated RARS and donor MNC
In the 24 h time interval after incubation onset Fas agonistic antibodies reduced overall MNC proliferation as determined by 3 H-thymidine incorporation in five of eight patients ( Figure  5 ). Two patients showed an increase of proliferation. G-CSF induced proliferation (P Ͻ 0.01) and the addition of G-CSF to Fas agonistic antibodies restored proliferation compared to Fas alone (P Ͻ 0.05) in RARS cultures. Fas ligation decreased MNC proliferation in three of six controls, while two of six did not change and one of six showed an increase in proliferation. The combination of G-CSF and Fas agonistic antibodies induced proliferation in four of four control samples. Similar changes were detected at later time points (data not shown).
G-CSF improves erythroid colony growth in RARS
Erythroid colony growth was reduced in six of eight patients. The reduction was severe in five of eight and moderate in one of eight (Table 2 ). In four of five patients with severely impaired erythroid colony growth, G-CSF increased the number of erythroid colonies, while one of five did not show any significant change. By contrast, in the patients with moderately reduced, or normal erythroid colony growth, G-CSF reduced the number of erythroid colonies. The number of myeloid colonies was reduced in patients compared to the controls (56 ± 36.4 vs 140 ± 49.7). Three of eight patients showed a G-CSF-induced decrease in CFU-GM, while five of eight increased. In all four controls G-CSF reduced erythroid colony growth, and myeloid colony growth was enhanced in three of four samples. Fas-ligation reduced erythroid colony growth in five of eight, and myeloid growth in seven of eight patients.
Discussion
The Fas death receptor has been implicated in apoptosis in MDS in numerous studies. [12] [13] [14] [15] Moreover, increasing hemoglobin levels in MDS patients in response to combined G-CSF and EPO therapy has been demonstrated in a number of clinical studies. [3] [4] [5] [6] [7] [8] [9] In the present work, focussed on a relatively homogenous subgroup of MDS patients, RARS, for which a common pathogenic mechanism can be postulated we found that addition of G-CSF in vitro inhibited caspase activation, the drop of ⌬ m and nuclear apoptotic changes after Fas ligation of RARS and control MNC. In patients with severely impaired erythroid colony growth, G-CSF also increased the number of erythroid colonies.
Our previous results revealed that the tetrapeptide caspase-3 inhibitor DEVD.fmk reduced apoptosis, increased prolifer- ation and enhanced erythroid colony growth in RARS patient cells. 27 By contrast, Bouscary and coworkers 28 used the caspase inhibitor z-VAD.fmk which significantly decreased caspase-3 activity and nuclear apoptotic morphology but failed to enhance colony growth. The discrepancy between these studies may be explained by the different spectrum of the inhibitors. z-VAD.fmk is known to be a pan-caspase inhibitor, 37 and may also display non-specific effects, not related to the inhibition of caspases, at higher concentrations (Ͼ100 M) such as those used by Bouscary et al. 28 Moreover it remains unclear whether caspase inhibition leads to survival of functional cells or not. Vercammen et al 38 suggested that blocking of apoptosis by z-VAD.fmk might direct the cells towards a necrotic cell death, while Ko et al 37 suggested that caspase inhibition using z-VAD.fmk may rescue cells from apoptosis and maintain their viability and clonogenic potential. Recently a beneficial effect of caspase 3 inhibition on clonogenic Leukemia potential was strongly supported by a French study, showing significantly higher caspase 3 activity in RA/RARS vs other MDS subtypes, and that the inhibitor DEVD-cho was significantly enhanced in particular erythroid colony growth in these subtypes. 39 Similar to what we observed, there was no effect of caspase inhibition on normal bone marrow. Thus, there is now multiple evidence that increased caspase activation plays an important role in ineffective erythropoiesis.
In our experiments, inhibition of caspase activation by G-CSF blocked Fas-induced apoptosis and the cells maintained their ability to proliferate. Interestingly, G-CSF reduced both caspase-8 and caspase-3-like activity in anti-Fas treated MNC suggesting that it inhibited the caspase cascade at a step prior to caspase-8 activation. A similar reduction in initiator and effector caspase activity was recently shown in GM-CSFtreated mature neutrophils. 40 In the proliferation assay, G-CSF induced a dramatic Nuclear apoptotic changes in RARS and control bone marrow cells. The percentage of apoptotic cells displaying nuclear DNA fragmentation as assessed by TUNEL staining is indicated in eight patients and three normal controls.
Figure 5
Proliferation of RARS and control bone marrow cells. Proliferation of MNC isolated from eight patients and six controls assessed by increase in the majority of cases ( Figure 5) while the effect of G-CSF alone on apoptosis measured as TUNEL positivity (data not shown) showed a less uniform pattern. We believe that the increased proliferation probably led to secondary phenomena in the cultures, such as deprivation of other essential medium factors, and that it would have been necessary to change culture conditions to allow analysis of small changes in nuclear apoptosis.
In RARS, the iron-overloaded morphology of the mitochondria is well described, although the underlying cause(s) in these changes and the functional consequences remain unclear. In line with previous studies on ligand-induced apoptosis, we found that loss of ⌬ m and increase of ROS in GpA-negative cells were late events compared to the activation of caspases. Scaffidi et al 41 has shown that some cell types can undergo Fas-induced apoptosis independently of mitochondrial alterations. Our data suggest that mitochondria do not play a critical role in Fas-induced apoptosis of nonerythroid cells, at least as assessed with the present method. Due to technical difficulties we were not able to use erythroid cells for FACS analysis and cannot at present provide data concerning mitochondrial changes in the actual cells that dis- na, not assessed.
Leukemia play iron-overloading. This remains to be elucidated in future experiments. Anti-apoptotic effects of G-CSF have been described previously by our group. 42 Philpott et al 43 have shown that G-CSF-mobilized peripheral blood stem cells are significantly less apoptotic than unstimulated peripheral blood CD34 cells. G-CSF can also block apoptosis and thus prolong survival of peripheral blood neutrophils. 40, 44 Recently, Hunter and coworkers 45 have shown that G-CSF activates the anti-apoptotic PI3-kinase, whose downstream targets have not been elucidated. Interestingly, the same kinase is activated by EPO. 46 These observations thus provide a tentative explanation for the synergistic effect of combined cytokine therapy as compared to the exclusive use of either G-CSF or EPO. Furthermore, EPO induces the anti-apoptotic protein Bcl-X L 47,48 while G-CSF inactivates the pro-apoptotic protein Bad 45 and downregulates Bax in mature neutrophils. 49 The work by Takahashi et al 50 confirms that there is no cross-reaction between Fas and the G-CSF receptor that could explain the reduced caspase activation. In addition, our own results indicate that G-CSF did not downregulate Fas expression (data not shown).
A positive effect of G-CSF on erythroid growth and maturation is suggested from our data and from clinical results, but the mechanism for this effect cannot easily be drawn from the present experiments since the caspase activity assays were performed on MNC cells. Moreover, a positive effect of G-CSF in the colony cultures was not observed in all patients. In our previous study, we showed that a short caspase inhibition of CD34 + cells before plating could improve erythroid clonogenic growth 27 and the French study adding caspase inhibition during the whole culture period showed even stronger positive effects. 39 We also showed that erythroid cells at the GPA+ level was not affected by caspase inhibition, and that caspase activity was lower in this compartment, suggesting that the important steps in erythroid apoptosis in RARS occur at maturation levels before GPA+ cells. The caspase assay is a cell consuming method and we did not have the opportunity to apply it on purified CD34 + cells from more than one RARS and one control (data not shown). These two experiments, however, verified the results obtained from the MNC cells, indicating that our interpretations are also valid for CD34 + cells. We are currently developing methods for detection of caspase activity in smaller cell populations. In less severe RARS patients, as in the normal controls, G-CSF promoted myeloid growth, in favor of erythroid growth. Clinically, these patients may also respond to EPO as monotherapy. More severe RARS, however, show a significantly better clinical response to the combination, and in vitro, an improved erythroid growth to G-CSF. Our hypothesis is that G-CSF mainly serves as a survival factor for cells at the CD34 + level, thus promoting early erythroid differentiation to a maturation stage where EPO may be active. Better methods to analyze the process of erythroid differentiation are warranted.
To conclude, G-CSF treatment in combination with EPO constitutes a promising anti-apoptotic and erythrogenic therapy in RARS patients. Future studies should aim at characterizing patient subgroups which benefit the most from this expensive treatment, and at a better understanding of the apoptotic triggers, including Fas ligation which are involved in MDS. Further understanding of the anti-apoptotic effects of G-CSF may also result in refined hypotheses about how to improve effective erythropoiesis in MDS. In vitro studies on subsets of bone marrow cells isolated from well-defined patient subgroups may serve as a suitable model for such studies.
